We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Cannabinoid Technologies Holdings Plc | LSE:OCTP | London | Ordinary Share | GB00BMVMRB86 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.115 | 0.10 | 0.13 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -5.95M | -0.0062 | -0.18 | 1.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/8/2023 07:25 | Nothing in the results this morning to suggest this share is going to fly any time soon but I'm happy to sit on my shares for the foreseeable future. I'm watching out for a possible fund raising exercise early next year though...." Cash is forecast to be fully utilised by April 2024." | jansky61 | |
21/8/2023 10:22 | Lack of any news...so some folk leaving but the numbers are small so I'm personally not too worried....the real step change in price is going to come with meaningful news. These fluctuations are are normal in periods if no news flow IMHO | jasko | |
21/8/2023 10:04 | Any reason for the drop today? | bibdaddy | |
15/8/2023 12:51 | I like what this companies trying to achieve, sure with success there could be many useful drugs, that could help many people, think there chances of success are good. | paulhopeful | |
15/8/2023 12:26 | I’m guessing we are headed to the 1 year high, with good results, maybe the 2 year high ? Then a placing, If the next stage is good, then all bets are of the table. | paulhopeful | |
31/7/2023 07:24 | Will the latest inflation data open the way for speculative small caps to come roaring back amidst the gloom of the past couple of years?https://total- | burtond1 | |
28/7/2023 23:05 | OCTP about to turn heads with its trials, They are still on for results Q3. Once the news confirms the drug is safe and without serious side effects it will roll on to Phase 2. This phase 1 results will surge OCTP closer to being one of those rare successful Pharmaceutical companies that their R&D actually pays dividends. @ £9M M/C will be long gone. Glad to be on board at such an early stage of success. Plenty news flow to follow. We are also seeing the price being suppress for some large buy orders, most sells are buys and with 2x 6M and 2M recent buys shows confidence. I just can't see the share price going down any further especially with recent Videos and announcements. MM's will have to let this go GLA | sep800 | |
27/7/2023 07:27 | Long time coming but excellent news nevertheless. It's the milestone we've all been waiting for and the results due in this qtr too. Good stuff | jasko | |
17/7/2023 16:24 | £3000, is that all? I have a bigger shareholding than most directors, it's about time more of them showed a bit of faith, if they haven't got "skin in the game" then we're in for a long wait. They have an opportunity to buy now so what are they waiting for? | jansky61 | |
17/7/2023 13:16 | 3000 pounds invested by CEO lol must be confident | itscominghome | |
17/7/2023 07:26 | No position here but interesting news all the same...but obviously this is very, very early stage of course and with minimal clinical detail at present. But in the broadest sense this is all positive incremental news for the cannabis space as a whole which is still coming off a very flat 2022....but various green shoots, across the industry as a whole, are beginning to emerge. KNB RNS'ing this morning are pushing ahead with 3000kg production facility in Spain (2 years off) which I've commented on this morning, contrasting it to Hellenic (HELD) who are apparently due to execute their maiden crop this quarter: Oakridge17 Jul '23 - 07:49 - 1049 of 1049 Edit 0 1 0 An interesting RNS at KNB this morning that is worth comparing and contrasting with HELD. Their partly owned (40%) subsidiary, Agritec, has a contract to develop a cannabis production site in Spain. They are a predicted 24 months away (yes - approx two years away) from being able to produce 3000kg annually...of which they will only have a partial share.....and that's if all goes to plan. I suspect a soft response by the mkt. Their CEO is very upbeat about this however and believes it will deliver significant revenues and shareholder value. Whilst it is good news for their own supply chain, the above figure and time lines help bring some sweeping perspective as to just how large HELD *could* become and where we are in respect of timing... HELD's license is good for 55,000kg annually and a site that can be incrementally scaled to match the size of that license. The bunkers (already built) that HELD intends using first are good for 1000kg, with further expansion across the site via POD agreements, the first of which should be via Demecan.... We were recently told that we were on schedule for the first cropping this quarter and we were also told further PODS were in the pipeline..... KNB's apparent enthusiasm for their partly owned 3000kg in approx 24 months brings some useful contrast to where HELD apparently are, I feel. A lot can happen in two years, but its reassuring to think KNB are taking that route with a 24 month window, growing to that fairly limited scale and in a country that will likely have higher costs than Greece. A few checkpoints still to be cleared at HELD of course as well as the clean execution and sale of our first crop......but should that happen and we get to see POD agreements arriving and being implemented, I should think it will inspire the market somewhat. We'll see. AIMO ADYOR etc. | oakridge | |
17/7/2023 07:13 | Jam tomorrow keep on selling | itscominghome | |
10/7/2023 15:22 | If you have researched properly what company you decide to invest in then OCTP has all the products to be fruitful. OCTP is not for day trading at this stage, nevertheless there are opportunities when the share price has fallen well below the value of a company that one should consider a time to buy or top-up. At this level it's a buy, especially with news of its phase 1 trials due. OCTP do not need to raise and still have £5M cash and are fully funded for its trials and research till 2024. All to their own, but patients will be rewarded. Buy, leave in a bottom drawer and come back next year, or trade on news GL | sep800 | |
10/7/2023 14:46 | This has to be the most ramped stock I've ever seen. In March this year it touched 1.5 and since then practical every post has said it's about to break out despite dropping over 40%. I got suckered into cannabis stocks but have accepted the reality If it looks like a duck and walks like a duck. | bobea | |
10/7/2023 10:38 | burtond1..I think many have missed how advanced OCTP are. These human phases are very short run. The product currently on trial phase 1 (on humans) is a safe product, Just needs confirming how effective these treatments are and if any side effects. We are not dealing with a new uncertain product but a product that is widely used in different forms. OCTP will make headways making sure its product will be accessible for production and registered as an alternative natural treatment. We should see north of 2p plus on these results and reaching back to the IPO 5p is most likely given the low M/C. We are fully funded till 2024 which means we have all the data and results for an approval without further short term funding. | sep800 | |
10/7/2023 08:19 | Time to look hard and close at debt free, cashed up Oxford Cannabinoid Technologies ask @TMSreach "...Prospective investors should look out for the next major stage in the company's journey, the completion of Phase I trials in Q3..."https://total-ma | burtond1 | |
07/7/2023 13:19 | I think this will close blue and 8.40 feels like a bargain price | soultrading | |
07/7/2023 13:19 | I bought more. | soultrading | |
22/6/2023 08:55 | Nah...can't see it myself IMO. Got to have more trial data that shows the drug's effectiveness in real patients. Unless of course big pharma has had an early look at the data available to date as to speak and are willing to 'gamble' on the candidates...but I must say that I believe that this quiet period will come to an abrupt end one way or another and without warning as this ship appears to be tightly run. AIMHO | jasko | |
21/6/2023 13:54 | Think this will be taken out by big pharma sooner than many think. | gotterdammerung |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions